Siemens Medical Solutions AG

SAN FRANCISCO, Jan. 13, 2025 /PRNewswire/ -- Gryphon Bio, Inc. has announced its pursuit of observational clinical studies with partners at multiple U.S. and international clinical sites to demonstrate the benefits of a novel panel of blood biomarkers for early detection and monitoring of traumatic brain injury (TBI) and Alzheimer's disease (AD). Combined with known risk factors, such as age and genetic variants, the Gryphon Bio studies are potential game-changers to monitor the treatment journey and develop novel therapeutics for active-duty soldiers, Veterans, adults, and children worldwide who suffer from this devastating disease. "TBI is an established risk factor for dementia and Parkinson's disease. Innovative biomarker studies at the interface of these and related disorders are critical to rapidly develop pragmatic tests to aid patients, caregivers, and providers in making informed care decisions today and to guide precision-medicine treatments in the future," said Dr. Raquel Garner, Director of Clinical Research, Sago Neuroscience Center, Sheba Medical Center. "TBI remains one of the leading causes of death and disability among children, as well as adults, worldwide. New blood tests for TBI will empower physicians as an aid-in-monitoring in pre-hospital, hospital, and post-hospital care settings to support clinical decisions based on this and other clinical assessments. It is time to prioritize innovative solutions to address this global brain health crisis," said Dr. Todd Kilbaugh, MD Director of the Resuscitation Science Center and Endowed Chair of Translational Science and Innovation, The University of Pennsylvania and The Children's Hospital of Philadelphia. Gryphon also announces the appointment of Anthony DeLizza as Chief Business Officer responsible for the oversight of Gryphon's biomarker validation studies, product development, FDA product clearance, and commercialization. Mr. DeLizza has a long career commercializing med-tech solutions including laboratory, point-of-care diagnostics and medical devices. He previously held positions at Syva Company (now Dade-Behring Diagnostics, Siemens), Johnson & Johnson, and a variety of diagnostic and medical device companies. Gryphon's novel blood tests for unexpected waves of 1000s of brain biomarkers (and therapeutic targets) in the blood of TBI patients. These novel biomarkers were discovered after more than 22 years of proteomic research by Gryphon's co-founders, Drs. William E. Haskins and Kevin Wang. Gryphon is backed by $13M+ in non-dilutive government grant awards and contracts Media Enquiries: [email protected] SOURCE Gryphon Bio, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

WASHINGTON--(BUSINESS WIRE)-- ELIQUENT Life Sciences, a global regulatory consulting firm for the life sciences industry, today announced the appointment of Steve Purtell as its new chief financial officer (CFO). This strategic addition to ELIQUENT’s executive team underscores the company’s commitment to financial excellence and sustainable growth. This press release features multimedia. View the full release here: Steve Purtell - Chief Financial Officer, ELIQUENT Life Sciences (Photo: Business Wire) “Steve’s appointment comes at a pivotal moment for ELIQUENT. As we unify the five Validant Group companies and expand our global footprint, Steve’s leadership and financial expertise will play a critical role in our continued growth,” said Tim Dietlin, Chief Executive Officer, ELIQUENT Life Sciences. In his role as CFO, Steve is responsible for directing and executing all of ELIQUENT’s finance activities. This includes partnering with the CEO and executive team to ensure the company’s financial direction aligns with the company’s strategic vision and long-term growth objectives. Steve will also serve as a key liaison to investors and the financial community while embedding a strong risk and compliance management framework across ELIQUENT’s growing global market. A seasoned finance executive with nearly 30 years’ experience, Steve has held key roles at multiple public companies across diverse industries. Steve joined ELIQUENT Life Sciences following more than 10 years at Six Flags, where he served in several finance-related roles, including Interim CFO. As a key advisor to the chief executive officer, Steve was responsible for managing external financial relationships, strategic communications, and mergers and acquisitions for the $1.5 billion entertainment company. Steve also held leadership roles at Siemens Healthcare, where he served as Vice President of Global Commercial Excellence, Vice President of Finance, and Treasurer of the company’s $25 billion healthcare division. Prior to joining Siemens Healthcare, Steve served in financial roles at Dade Behring, IMC Global, and GATX. Before his corporate career, Steve served as a Combat Engineer Officer in the U.S. Army and was awarded a Bronze Star Medal in the Persian Gulf War. Steve received a B.S. degree in Civil Engineering from the U. S. Military Academy at West Point and an MBA from the Wharton School. About ELIQUENT Life Sciences ELIQUENT Life Sciences is the fusion of five global regulatory consultancies: Validant, Greenleaf Health, DataRevive, Oriel Stat-a-Matrix, and IDEC. The ELIQUENT team works cross-functionally to deliver the global solutions that pharmaceutical, biotechnology, and medical device companies need to gain and maintain authorization for the products. ELIQUENT’s comprehensive services support innovators across therapeutic modalities, phase-based pathways, and major global markets. ELIQUENT’s continued growth is supported by GHO Capital, the European specialist investor in healthcare. About GHO Capital Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. We apply global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market leading businesses of strategic global value. Our proven investment track record reflects the unrivalled depth of our industry expertise and network. We partner with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit .

MeMed Further Solidifies Board of Directors with Appointment of Scott Garrett HAIFA, Israel; BOSTON, MA – 9 November, 2023 – MeMed, a leader in host response technologies, today announces the appointment of Scott Garrett to its Board of Directors. Scott Garrett is currently a Senior Operating Partner at Water Street Healthcare Partners, a private equity firm focused solely on healthcare investments. He has more than 35 years of experience leading global healthcare businesses with emphasis on diagnostics and life sciences. Prior to Water Street, Scott served as chairman, president & CEO of Beckman Coulter, Inc. He led the company through an eight-year period of growth and value creation establishing it as a leader in biomedical testing. Scott began his career in R&D at Baxter International. He advanced to group vice president and CEO of Baxter’s global diagnostics business and led the buyout of that business in 1994, becoming the CEO of its successor, Dade Behring, Inc. Scott has been an active member of AdvaMed for many years and was the founding chairman of AdvaMedDx, an industry association focused on in vitro diagnostics. He is chairman emeritus of AdvaMedDx and also chairs the Boards of Water Street companies ALCOR Scientific, Pathnostics and Avantik, Inc. Scott serves on two public company Boards: Hologic, Inc. and HCW Biologics. Mr. Scott Garrett, commented, “I've always shared MeMed's conviction that innovative technology holds the power to enhance lives and elevate patient care. I'm truly enthusiastic about my appointment to MeMed's Board of Directors and eagerly anticipate helping the MeMed team achieve its operational and strategic goals.” Dr. Eran Eden, CEO of MeMed, noted, “We’re excited to welcome Scott Garrett to our Board and leadership team. His addition marks another significant step in the strategic expansion of our Board, bringing deep experience in the commercialization of leading diagnostic products, company building, and strategic partnerships. I look forward to working with Scott to further our mission and establish MeMed as a leader in the emerging field of advanced host-response.” About MeMed At MeMed, our mission is to translate the immune system’s complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society. By leveraging expertise in host-response profiling and machine-learning algorithms, MeMed is creating a portfolio of tests that address tough clinical dilemmas. Follow and connect with MeMed via LinkedIn, Twitter, and Facebook. MeMed Contact:Amy Crosby, Director of Demand Generation, MeMedpr@me-med.com Media relations contact:ICR Consilium MeMed@consilium-comms.com